Soybean Isoflavone Composition for Insulin Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity and diabetes, such as Xenical and Reductil, primarily inhibit appetite and fat absorption rather than promoting fat burning, which is insufficient for completely addressing insulin resistance and safety concerns remain unestablished, necessitating a novel substance that effectively reduces body fat and improves insulin sensitivity.
Innovation Solution
A composition containing isoflavone, L-carnitine, caffeine, and arginine, which promotes lipolysis and fat burning, reducing body fat and improving insulin sensitivity by increasing adiponectin expression, thereby treating obesity and diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Weight of moving object
If conventional obesity treatment drugs (Xenical, Reductil) are used to inhibit appetite and fat absorption, then body weight reduction is achieved, but insulin resistance is not sufficiently addressed and serious side effects occur
Solution Approach 1:
The patent changes the mechanism of action from appetite suppression to fat metabolism promotion. The composition uses L-carnitine to enhance fatty acid oxidation, isoflavone to regulate lipid metabolism, and caffeine to stimulate lipolysis, fundamentally altering how weight loss is achieved while improving safety profile
Solution Approach 2:
The patent combines multiple natural ingredients (L-carnitine, isoflavone, caffeine, arginine) into a composite formulation that works synergistically to promote fat burning and improve insulin sensitivity, replacing single-mechanism conventional drugs with a multi-component system
2Weight of moving object
If conventional obesity treatment drugs are used to reduce body weight, then weight loss is achieved, but insulin resistance remains unresolved
Solution Approach 1:
The patent creates a multi-functional composition that simultaneously achieves weight loss, improves insulin sensitivity, regulates lipid metabolism, and enhances fat oxidation. Each ingredient contributes multiple functions: L-carnitine aids both fat transport and insulin sensitivity, while isoflavone provides both lipid regulation and antioxidant effects
Solution Approach 2:
The patent shifts the therapeutic parameter from simple weight reduction to comprehensive metabolic improvement, including insulin sensitivity enhancement through adiponectin upregulation and inflammatory marker reduction, addressing the root cause rather than just the symptom
3Weight of moving object
If fat absorption is inhibited to reduce body weight, then weight loss occurs, but fat burning and decomposition are not promoted
Solution Approach 1:
Instead of blocking fat absorption, the patent inverts the approach by actively promoting fat decomposition and oxidation. The composition stimulates lipolysis through caffeine, enhances fatty acid transport via L-carnitine, and upregulates fat-burning enzymes, transforming stored fat into energy rather than preventing its absorption
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed herein is the use of a composition, containing isoflavone- containing soybean extract, L-carnitine, caffeine and arginine as active ingredients, for the treatment of obesity and diabetes. The disclosed composition contains isoflavone -containing soybean extract, carnitine, caffeine and arginine in the form of a mixture, and thus shows not only the effect of promoting lipolysis and fat burning, but also anti-obesity and anti-diabetic effects by increasing the expressions of adiponectin and Glut4 genes to restore insulin sensitivity.